Many thanks for making this document available. I agree with the authors, it is time to be logical in choosing which new treatment should be given to a particular person based on data. I think that paper is very encouraging for where (we) are headed with the current trial treatments.
Thanks for sharing this Stephen - I spend a lot of time stressing about how to proceed in the event of a recurrence and having real data to discuss with the medical profession has to be helpful. I think this is an encouraging step forward and I feel it provides some good questions to ask when the time comes, but I can't pretend I understand all of it! It seems to suggest DC Vax remains a good option but there are additional factors to consider and lots of caveats relating to the scorecard itself. As and when you are able to read it, if you could provide a layperson's summary I would be very grateful!
Many thanks for making this document available. I agree with the authors, it is time to be logical in choosing which new treatment should be given to a particular person based on data. I think that paper is very encouraging for where (we) are headed with the current trial treatments.
ReplyDeleteThanks for sharing this Stephen - I spend a lot of time stressing about how to proceed in the event of a recurrence and having real data to discuss with the medical profession has to be helpful. I think this is an encouraging step forward and I feel it provides some good questions to ask when the time comes, but I can't pretend I understand all of it! It seems to suggest DC Vax remains a good option but there are additional factors to consider and lots of caveats relating to the scorecard itself. As and when you are able to read it, if you could provide a layperson's summary I would be very grateful!
ReplyDeleteI'll put that on my to-do list!
DeleteThank you :-)
Delete